nonsense mutation Duchenne muscular dystrophy
PTC Therapeutics to file new Phase III data for genetic muscle disorder drug in Canada
March 15, 2016Manufacturing and Production, Research and Development Canada, PTC Therapeutics, Translarna, nonsense mutation Duchenne muscular dystrophy, phase III
PTC Therapeutics (Nasdaq: PTCT) said it does not expect the Canadian regulators to review its trial drug to treat a …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
